Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-search-preview· OpenAIHugging Face LMArena Search Arena 24K

Immunotherapy in Ovarian Cancer ORR

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Perplexitysonar-reasoning-pro-high’s answer.
  1. User

    Immunotherapy in Ovarian Cancer ORR

  2. Assistant

    Immunotherapy has been explored as a treatment option for ovarian cancer, with varying overall response rates (ORR) depending on the specific therapy and patient population.

    For instance, in a Phase II study involving 119 patients with advanced ovarian cancer who had not responded to standard therapies, treatment with abagovomab—a monoclonal antibody vaccine—resulted in a significant extension of survival time for patients who developed antibodies against the tumor. These responders, comprising nearly 70% of the study population, experienced a median survival of 23.4 months compared to 4.9 months in non-responders[1].

    It's important to note that the effectiveness of immunotherapies can vary widely based on factors such as the specific agent used, patient characteristics, and the stage of the disease. Therefore, while some immunotherapies have shown promise, their overall response rates in ovarian cancer treatment are not uniform and require further investigation through clinical trials.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.